Introduction Fundstrat’s Tom Lee cautions investors to prepare for a painful start to 2026 across crypto and traditional markets, shaped by geopolitical frictionsIntroduction Fundstrat’s Tom Lee cautions investors to prepare for a painful start to 2026 across crypto and traditional markets, shaped by geopolitical frictions

Fundstrat’s Lee Warns of Painful 2026 Market Decline

Fundstrat's Lee Warns Of Painful 2026 Market Decline

Introduction

Fundstrat’s Tom Lee cautions investors to prepare for a painful start to 2026 across crypto and traditional markets, shaped by geopolitical frictions, before a gradual recovery toward year-end. Speaking on The Master Investor Podcast with Wilfred Frost, Lee argued that 2026 could mirror 2025 in terms of macro and sectoral tailwinds for blockchain and artificial intelligence, even as tariffs and political divides threaten an immediate, sustained rally.

Key Takeaways

  • A difficult opening phase for crypto and equities is expected in 2026, followed by a rebound as policy and macro conditions shift.
  • Geopolitical tensions, tariffs, and domestic political divides are likely to cap near-term upside potential.
  • A new all-time high for Bitcoin would signal that deleveraging in the market has run its course.
  • Analysts anticipate metals and energy sectors to outperform crypto again in 2026, with gold remaining a staple for portfolios.

Tickers mentioned: $BTC

Sentiment: Neutral

Price impact: Neutral. Near-term volatility is expected, with a predicted year-end recovery shaping the tone for risk assets.

Trading idea (Not Financial Advice): Hold. The macro backdrop suggests waiting for clearer easing signals and sector rotations before committing larger allocations.

Market context: The outlook ties crypto’s fate to macro policy shifts, inflation dynamics, and evolving geopolitical risk, underscoring a broader cycle of volatility and potential regime change.

Rewritten article body

Fundstrat’s head of research, Tom Lee, has warned that investors should brace for a painful decline across both crypto and stock markets in 2026, driven largely by geopolitical frictions that could weigh on risk appetite early in the year. In a recent interview on The Master Investor Podcast with Wilfred Frost, Lee outlined a cautious path for 2026, suggesting that the year may resemble 2025 in terms of underlying tailwinds for blockchain and artificial intelligence, while tariffs and political rifts limit the pace of any initial rally.

Lee projected a stock market correction of roughly 15% to 20% in the coming year, but he remained upbeat about the year-end trajectory. He attributed part of this resilience to a more dovish stance from the U.S. central bank and the end of quantitative tightening, arguing that those factors could provide the fuel for a late-year acceleration in equities and risk assets. He also noted that Washington’s selective prioritization of “winners and losers” could influence which sectors outperform, underscoring the role of policy signaling in shaping market leadership.

On Bitcoin, Lee maintained a constructive stance, expecting the benchmark cryptocurrency to reach a new all-time high within 2026. While he stopped short of revisiting his earlier, higher price targets, the emphasis remained on the psychological and technical significance of a fresh peak, should it materialize. A new all-time high would, in his view, serve as a practical signal that a major deleveraging cycle has run its course and that leverage within the market has effectively cooled.

Lee also pointed to crypto’s recent divergence from gold as a reflection of deleveraging dynamics that periodically unsettle the market. He described the leverage cycles as a kind of “central bank of crypto,” capable of distorting risk pricing and liquidity, especially for market makers who serve as the liquidity backbone for the space. Until there is broader mainstream adoption and more substantial institutional participation, these disruptions are likely to persist, he warned, keeping volatility elevated even as long-term growth narratives in blockchain and AI remain intact.

The interview touched on a broader macro narrative: if policy remains patient and inflation decelerates, 2026 could ultimately reward those sectors aligned with real-world adoption—while the crypto space could prove more vulnerable to episodic shocks during a transitional period. Lee emphasized that the health of the sector hinges on institutional confidence and regulatory clarity, which, in his view, have yet to reach the critical mass required for a persistent, self-sustaining rally.

Turning to a cross-asset frame, Lee cited metals and energy as potential outperformers in 2026, echoing other analysts who see real assets as a hedge against macro volatility. Gold, in particular, remains a recommended staple for balanced portfolios, offering a counterweight to crypto’s susceptibility to leverage-driven downturns. Into The Cryptoverse’s Benjamin Cowen added a complementary perspective, noting that metals outperformed crypto in 2025 and are likely to do so again in 2026. Yet Cowen also warned of a looming correction for metals later in the year, cautioning that crypto could face sharper declines if leverage reaccelerates amid shifting sentiment.

In closing, the market sage counsel remained consistent: trade the market you have, not the market you want. The year ahead appears poised for a continued tug-of-war between structural advances in blockchain and AI and the blunt realities of macro policy and geopolitics, a dynamic that will keep both crypto and traditional markets calibrated to a higher degree of risk than in the calm of prior cycles.

This article was originally published as Fundstrat’s Lee Warns of Painful 2026 Market Decline on Crypto Breaking News – your trusted source for crypto news, Bitcoin news, and blockchain updates.

Market Opportunity
Love Earn Enjoy Logo
Love Earn Enjoy Price(LEE)
$1.08
$1.08$1.08
0.00%
USD
Love Earn Enjoy (LEE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26